• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

elililly

Lilly to add Welldoc app to future insulin pen

February 25, 2021 By Nancy Crotti

Eli Lilly

Eli Lilly (NYSE:LLY) and Welldoc announced a collaboration and licensing agreement to integrate Welldoc’s software into Lilly’s connected insulin pens, which are in development. Lilly and Welldoc will create a new version of Welldoc’s BlueStar insulin management software, which will integrate insulin dosing data for several Lilly insulins. The BlueStar app has FDA 510(k) clearance for […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance Tagged With: Eli Lilly & Co., elililly, welldoc

Clinical trials ramping up for potential coronavirus-fighting drugs

April 13, 2020 By Sean Whooley

Bausch Health (NYSE:BHC) announced today that it initiated a clinical trial program in Canada to investigate the use of Virazole for treating COVID-19. With today’s announcement, Bausch joins Eli Lilly (NYSE:LLY) and Care Access Research, which both announced clinical testing of coronavirus therapies last week. Bausch’s Virazole is currently approved in the U.S. and Canada, among other […]

Filed Under: Business/Financial News, Clinical Trials, Diagnostics, Featured, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: Bausch Health, Care Access Research, coronavirus, COVID-19, elililly, FDA

Lilly to integrate DexCom CGMs in automated dosing system

December 16, 2019 By Sean Whooley

Eli Lilly (NYSE:LLY) announced that it will integrate Dexcom (NSDQ:DXCM) products into its personalized diabetes management system, now under development. Under the new, non-exclusive agreement, Indianapolis-based Lilly will use San Diego-based Dexcom’s continuous glucose monitoring (CGM) devices in pen-based and pump-based platforms in Lily’s diabetes management system. The pen-based platform is designed to integrate personalized data from […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: Dexcom, DexCom Inc., Eli Lilly & Co., elililly

Cigna lowers insulin price to $25 per month

April 3, 2019 By Nancy Crotti

Under pressure from patients and the FDA, Cigna (NYSE:CI) and Express Scripts said today that they will lower the price of insulin to $25 per month for some patients. Three firms — Eli Lilly, Novo Nordisk and Sanofi — control 90% of the global insulin market and produce all the insulin used in the U.S. […]

Filed Under: Business/Financial News, Diabetes, Featured, Food & Drug Administration (FDA), Uncategorized Tagged With: cigna, elililly, expressscripts, FDA, novonordisk, sanofi

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS